Charlene McEvoy, MD
Pulmonary Disease · Saint Paul, MNNPI 1295708931
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $11,375 of the $12,777 with a category attached, or 89.0%. GSK accounts for 89.0% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $4,879 and has fallen 95.0% since, to $246 in 2025. Among pulmonary disease clinicians in MN with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 28 payments — averaging $456.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$11K
- Philips North America LLC$684
- Inari Medical, Inc.$337
- 3b Medical, Inc.$125
- Astrazeneca UK Limited$113
- Pulmonx Corporation$89
- plus $54 from 2 others
Across 132 payments — averaging $63,433 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$7.3M
- GSK$1M
- Boston Scientific$15K
- Boehringer Ingelheim International GmbH$4K
What the payments were for
- Consulting fees$11,37589%
- Food & beverage$1,38611%
- Education$160%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 3 | $11,375 |
| Philips North America LLC | 16 | $684 |
| Inari Medical, Inc. | 2 | $337 |
| 3b Medical, Inc. | 1 | $125 |
| Astrazeneca UK Limited | 1 | $113 |
| Pulmonx Corporation | 1 | $89 |
| Itamar Medical Inc | 3 | $38 |
| Insmed, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$337
- CT THROMBECTOMY SYSTEM KIT$337
- inCourage$215
- LUNA$125
How this compares
$12,777 in reported general payments places this provider in the 90th percentile of 261 pulmonary disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NucalaMepolizumab | 39 | $236,343 |
| Spiriva RespimatTiotropium Bromide | 313 | $215,198 |
| Dupixent SyringeDupilumab | 27 | $101,054 |
| Dupixent PenDupilumab | 25 | $94,734 |
| Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate | 256 | $85,268 |
| DuleraMometasone/Formoterol | 158 | $79,180 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 44 | $46,945 |
| SymbicortBudesonide/Formoterol Fumarate | 77 | $34,465 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 33 | $24,362 |
| BreynaBudesonide/Formoterol Fumarate | 62 | $19,086 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $15,416 |
| Incruse ElliptaUmeclidinium Bromide | 25 | $11,093 |
| Pulmicort FlexhalerBudesonide | 26 | $10,575 |
| AlvescoCiclesonide | 13 | $9,753 |
| Advair HfaFluticasone Propion/Salmeterol | 16 | $9,222 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKNucala, Trelegy Ellipta, Breo Ellipta, Incruse Ellipta | $11,375 | $309,797132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 261 pulmonary disease providers in Minnesota.
Other pulmonary disease in Saint Paul
- Anuja SharmaSaint Paul$11K
- David TeetersSaint Paul$5K
- Tameem RezanSaint Paul$2K
- Marshall HertzMinneapolis$289K
- David IngbarMinneapolis$272K
- Jonathan HovdaMinneapolis$139K
- Hilary DubrockRochester$102K
- Ulrich SpecksRochester$77K
- Hyun KimMinneapolis$77K
- Jagdeep BijwadiaRochester$54K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.